Clinical Trial Detail

NCT ID NCT02227914
Title Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Onyx Therapeutics, Inc.
Indications

hepatocellular carcinoma

Therapies

Oprozomib

Sorafenib

Age Groups: adult

No variant requirements are available.